Press Release

  View printer-friendly version

« Back

Collegium Announces the Launch of OpioidIQ

September 6, 2016 at 7:00 AM EDT
OpioidIQ encourages responsible opioid prescribing and provides educational tools designed to prevent abuse and misuse of opioids

CANTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announces the launch of OpioidIQ, an online educational tool to assist physicians and other healthcare providers with more effective pain management (Available at: The goal of OpioidIQ is to connect healthcare providers to information and resources aimed at supporting the safe and effective management of their patients with chronic pain who are appropriate for treatment with an opioid analgesic.

OpioidIQ provides physicians and other allied healthcare providers with tools to assess which patients are appropriate for opioid analgesics and important topics that need to be addressed with patients when deciding to treat them with an opioid analgesic, including:

  • Appropriate opioid use
  • Risks of unintentional misuse and abuse
  • Enhancing communications between patients and healthcare providers
  • Resources for providing information to patients and caregivers to avoid unintentional opioid misuse
  • Role of abuse-deterrent formulations (ADFs)

“Up to 1 in 4 patients misuse their opioid medication, and many of those patients are doing so unintentionally1” said Michael Heffernan, Founder, President & CEO of Collegium. “As part of our commitment to delivering safe and effective solutions for patients, we’re pleased to launch OpioidIQ. This educational platform will not only bring much needed awareness to the issue of opioid misuse, but also help clinicians identify the risk of unintentional misuse, enhance patient communication, and optimize pain management.”

“Opioids should only be prescribed after alternative non-opioid treatment options have been fully explored. Once a clinician has decided to prescribe an opioid to a patient, the clinician then needs to make it a point to ask the patient how he/she is taking his/her medicines. For example, are they ever crushing, chewing, or dissolving them prior to taking them,” said Dr. Jeff Gudin, Director of Pain Management and Palliative Care at the Englewood Hospital and Medical Center in New Jersey. “Having the tools to start those conversations could mean the difference between life and death.”

For more information, visit

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and commercializing products for the treatment of patients suffering from chronic pain and other diseases.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our products and product candidates; the existence of any patent infringement or similar litigation relating to any of our products or product candidates, and costs and delays associated with such litigation; the size and growth potential of the markets for our product and product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product and product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

1 Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576.

Douglas Carlson
Vice President, Corporate Development

Primary Logo

Collegium Pharmaceutical, Inc